Business Wire

YOKOGAWA-ELECTRIC

16.9.2020 09:02:17 CEST | Business Wire | Press release

Share
Yokogawa Survey Finds Two-Thirds of Process Industry Companies Are Anticipating Fully Autonomous Operations by 2030

Yokogawa Electric Corporation (TOKYO: 6841) today revealed the results of a global end-user survey on the outlook for industrial autonomy*, which shows that 64% of respondents from companies in process industries are anticipating fully autonomous operations by 2030. The survey provides an in-depth view of future trends in automation and autonomy, business priorities, and technologies being deployed in key process industries including oil and gas, pharmaceuticals, chemicals, petrochemicals, and power generation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005058/en/

Key Insights

Companies are moving to fully autonomous operations by 2030, and will invest in technologies that aid decision-making

Sixty-four percent of respondents stated that they expect to reach autonomous operations in their primary operations by 2030. Eighty-nine percent said their companies currently have plans to increase the level of autonomy in their operations. Regarding their current status, 64% said that they are conducting or are piloting semi-autonomous or autonomous operations, while 67% expect significant automation of most decision-making processes in plant operations by 2023.

Cyber security (51%), cloud, analytics, and big data (47%), and artificial intelligence (42%) are three key areas in which companies are planning significant investment over the next three years. These will enable organizations to make better decisions across a greater span of control.

COVID-19 has put the brakes on economic growth in 2020 but will be a catalyst for the medium- to long-term growth of industrial autonomy.

COVID-19 has arguably presented a great impetus for industrial autonomy moving forward. A higher priority is now being placed on the ability to continue running operations without workers needing to be present. A majority of respondents are expecting to increase their investment in autonomous operations as a direct result of COVID-19.

Respondents were also asked to rank the top four applications in which they were directing investment as a result of the COVID-19 pandemic. Unsurprisingly, remote operations and remote servicing came out as two of the key applications for which priorities have increased, with a respective 36% and 30% of participants selecting them. The ability to conduct work without the need for workers to be present in a hazardous environment provides significant safety and cost benefits.

The survey also uncovered significant differences across industries in post-COVID-19 investment priorities. For example, compared with other industries, conventional power generation and chemical/petrochemical participants placed a greater focus on investments in worker safety.

Regional trends

The survey revealed regional differences in investment in new technologies and the push to industrial autonomy. Relative to other regions, Asia-Pacific is the most engaged in the shift to industrial autonomy. The survey found that the proportion of companies in Asia-Pacific that are prioritizing investment in autonomous systems for operations is 18% to 27% higher than other regions. This is a key statistic and shows that funding is being directed into autonomous operations in the region. Seventy-one percent of respondents in Asia-Pacific felt that they would attain fully autonomous operations in ten years' time, compared with just 58% in North America and 56% in Western Europe.

“From this research study, we have confirmed our perception that the shift from industrial automation to industrial autonomy, which we call IA2IA, is going to gain momentum over the next decade. As COVID-19 will accelerate this trend, and companies' interest in introducing related technologies continues to be strong, Yokogawa can support customers in strengthening their competitiveness step by step based upon our roadmap to autonomous operations,” said Tsuyoshi Abe, senior vice president and head of the Marketing Headquarters at Yokogawa.

Yokogawa believes the digital transformation of companies’ manufacturing and production operations will lead towards autonomous operations; the results of the survey demonstrate that companies are prioritizing and investing in the technologies of tomorrow in order to make this a reality.

The survey highlight report can be downloaded from the following website.

https://www.yokogawa.com/special/ia2ia/outlook/

* The “Global End-user Survey on the Outlook for Industrial Autonomy” was conducted on behalf of Yokogawa by research company Omdia among 504 decision-makers in process industry companies between June and July 2020.

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 114 companies spanning 62 countries, generating US$3.7 billion in sales in FY2019. For more information, please visit www.yokogawa.com .

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

Link:

ClickThru

Social Media:

https://www.facebook.com/Yokogawa-127328307136/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye